-
公开(公告)号:US06333441B1
公开(公告)日:2001-12-25
申请号:US08026681
申请日:1993-03-04
申请人: Fumie Sato , Katsuaki Miyaji , Takehiro Amano
发明人: Fumie Sato , Katsuaki Miyaji , Takehiro Amano
IPC分类号: C07C505
CPC分类号: C07D309/12 , C07B35/02 , C07B2200/09 , C07C5/09 , C07C29/17 , C07C51/36 , C07C69/007 , C07C2523/44 , C07F7/1892 , C07C33/03
摘要: A cis-olefin of the formula: R1—CH═CH—R2 is prepared by reducing an alkyne of the formula: R1—C≡C—R2 with formic acid in the presence of a palladium catalyst. R1 and R2 are independently selected from the group consisting of a hydrogen atom, ester group, substituted silyl group, carboxyl group, cyano group, aliphatic C1-C20 hydrocarbon group, and phenyl group. The cis-olefin which is a useful intermediate for the synthesis of fine chemicals is selectively produced in high yields.
摘要翻译: 通过在钯催化剂存在下用甲酸还原具有下式的R 1 -C = C-R 2的炔来制备下式的顺式烯烃:R1-CH = CH-R2。 R1和R2独立地选自氢原子,酯基,取代的甲硅烷基,羧基,氰基,脂族C1-C20烃基和苯基。 作为合成精细化学品的有用中间体的顺式烯烃以高产率选择性地生产。
-
公开(公告)号:US5648526A
公开(公告)日:1997-07-15
申请号:US256924
申请日:1994-07-29
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: B01J31/22 , B01J31/24 , C07B61/00 , C07C405/00
CPC分类号: B01J31/2404 , B01J31/0237 , B01J31/0267 , B01J31/04 , B01J31/223 , B01J31/2282 , B01J31/2291 , C07C405/00 , B01J2531/824 , Y02P20/55
摘要: Object: To produce E-prostaglandins in a high yield and in a short time with suppressed formation of isomers.Structure: A process for preparing E-prostaglandins represented by the formula: ##STR1## (wherein A, R.sup.6 and R.sup.7 represent respectively an arbitrary group which does not participate in the reaction; B represents a vinylene or ethynylene group; and R.sup.4 and R.sup.5 may be the same or different from each other and each represents a hydrogen atom or a protective group of the hydroxyl group) which comprises reacting allyl esters of E-prostaglandins represented by the formula: ##STR2## (wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a lower alkyl group, an alkenyl group or an aryl group; and A, B, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined above) with at least one substance selected from the group consisting of bases and formic acid in the presence of a zero- or divalent palladium complex or a salt thereof.
摘要翻译: PCT No.PCT / JP93 / 00115 Sec。 371日期1994年7月29日第 102(e)日期1994年7月29日PCT提交1993年2月2日PCT公布。 公开号WO93 / 16041 日期1993年8月19日目的:以高产率和短时间产生E-前列腺素,抑制异构体的形成。 结构:由下式表示的E-前列腺素的制备方法:其中A,R6和R7分别表示不参与反应的任意基团; B表示亚乙烯基或亚乙炔基,R4和R5可以 彼此相同或不同,并且各自表示氢原子或羟基的保护基),其包括使由下式表示的E-前列腺素的烯丙基酯反应(其中R1和R2可以相同或相同) 彼此不同,各自表示氢原子或低级烷基; R 3表示氢原子,低级烷基,烯基或芳基; A,B,R 4,R 5,R 6和R 7如上所定义 上述)与至少一种选自碱或甲酸的物质在零或二价钯络合物或其盐的存在下反应。
-
公开(公告)号:US5583158A
公开(公告)日:1996-12-10
申请号:US416871
申请日:1995-04-19
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: A61K31/557 , C07C405/00
CPC分类号: C07C405/0025 , C07C405/0033
摘要: A prostaglandin E.sub.1 analogue represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; and X is an oxygen atom and R.sup.2 represents ##STR2## or X is a sulfur atom and R.sup.2 represents ##STR3## The compound has a strong and prolonged inhibitory action for platelet aggregation and is useful for treatment of various thrombotic diseases including peripheral circulatory disturbance.
摘要翻译: PCT No.PCT / JP93 / 01510 Sec。 371日期1995年04月19日 102(e)日期1995年4月19日PCT提交1993年10月20日PCT公布。 公开号WO94 / 08961 日本1994年4月28日由式
表示的前列腺素E1类似物,其中R1表示氢原子或C1-C6烷基; X是氧原子,R2表示 或 或X是硫原子,R2代表血小板聚集的作用,可用于治疗各种血栓形成疾病,包括外周循环障碍。 -
公开(公告)号:US5599838A
公开(公告)日:1997-02-04
申请号:US606440
申请日:1996-02-23
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: C07C405/00 , A61K31/21
CPC分类号: C07C405/0033
摘要: A prostaglandin derivative represented by the formula: ##STR1## wherein X is halogen atom R.sup.1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R.sup.2 is a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkylmethyl group having 4 to 10 carbon atoms or a cycloalkylethyl group having 5 to 12 carbon atoms, or a salt thereof, which has an excellent lowering action of intraocular pressure and improving actions of renal diseases, ischemic heart diseases and heart failure.
摘要翻译: 由下式表示的前列腺素衍生物:其中X为卤素原子,R1为氢原子或碳原子数为1〜6的烷基,R2为碳原子数3〜10的环烷基,环烷基甲基为4 至10个碳原子或具有5至12个碳原子的环烷基乙基或其盐,其具有优异的眼内降低作用和改善肾病,缺血性心脏病和心力衰竭的作用。
-
公开(公告)号:US5449815A
公开(公告)日:1995-09-12
申请号:US137090
申请日:1993-10-19
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: C07C405/00
CPC分类号: C07C405/00
摘要: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, and R.sup.2 is an alkyl group having 3 to 6 carbon atoms, an alkenyl group having 3 to 6 carbon atoms), or a salt thereof.
摘要翻译: PCT No.PCT / JP92 / 00514 Sec。 371日期:1993年10月19日 102(e)日期1993年10月19日PCT 1992年4月21日PCT PCT。 WO92 / 18473 PCT出版物 日期:1992年10月29日。目的:提供与现有技术的前列腺素E1相比,具有更优异的药物作用,更长的作用时间和更少的副作用的新型前列腺素E1类似物。 结构:由下式表示的PGE1类似物:< IMAGE>(其中,R 1为氢原子,碳原子数为1〜6的烷基或烯丙基,R 2为碳原子数3〜6的烷基,烯基 具有3〜6个碳原子的基团)或其盐。
-
公开(公告)号:US5639899A
公开(公告)日:1997-06-17
申请号:US133171
申请日:1993-10-19
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: C07C405/00 , C07C59/00
CPC分类号: C07C405/00
摘要: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein A is a vinylene group or an ethynylene group, R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, R.sup.2 is a branched aliphatic hydrocarbon group having 5 to 10 carbon atoms), or a salt thereof.
摘要翻译: PCT No.PCT / JP92 / 00513 Sec。 371日期:1993年10月19日 102(e)日期1993年10月19日PCT 1992年4月21日PCT PCT。 第WO92 / 18472号公报 日期1990年10月29日二氧化物目标:提供与现有技术的前列腺素E1相比,具有更优异的药物作用,更长的作用时间和更少的副作用的新型前列腺素E1类似物。 结构:由下式表示的PGE1类似物:其中A是亚乙烯基或亚乙炔基,R 1是氢原子,具有1至6个碳原子的烷基或烯丙基,R 2是支链脂族 具有5〜10个碳原子的烃基)或其盐。
-
公开(公告)号:US5491254A
公开(公告)日:1996-02-13
申请号:US373226
申请日:1995-01-19
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: C07C405/00 , C07C177/00 , A61K31/557
CPC分类号: C07C405/0016 , C07C405/00
摘要: ObjectNovel PG derivatives having an excellent platelet aggregation inhibition activity are provided.ConstructionProstaglandin derivatives represented by formula: ##STR1## and salts thereof.
摘要翻译: 提供了具有优异的血小板聚集抑制活性的新型PG衍生物。 前述前列腺素衍生物,其结构式如下:< IMAGE>及其盐。
-
公开(公告)号:US5545666A
公开(公告)日:1996-08-13
申请号:US290745
申请日:1995-04-19
申请人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人: Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号: C07C405/00 , C01C405/00 , A61K31/557
CPC分类号: C07C405/0016
摘要: A prostaglandin derivative represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.2 represents a cyclohexyl group or a cyclopentylmethyl group. This compound has physiological activities such as platelet aggregation-inhibiting action, renal blood vessel and coronary blood vessel-dilating actions and the like, and is useful for treatment of renal failure and diseases of circulatory organs.
摘要翻译: PCT No.PCT / JP93 / 01493 Sec。 371日期1995年04月19日 102(e)1995年4月19日PCT PCT 1993年10月18日PCT公布。 公开号WO94 / 08959 日本1994年4月28日由式
表示的前列腺素衍生物,其中R1表示氢原子或C1-C6烷基,R2表示环己基或环戊基甲基。 该化合物具有血小板聚集抑制作用,肾血管和冠状血管扩张作用等的生理活性,可用于治疗肾衰竭和循环器官疾病。 -
公开(公告)号:US4420631A
公开(公告)日:1983-12-13
申请号:US379632
申请日:1982-05-19
申请人: Takehiro Amano , Toshihisa Ogawa , Kensei Yoshikawa , Yoshinori Shiobara , Tatsuhiko Sano , Yutaka Ohuchi , Tohru Tanami , Shoichi Ito , Jiro Sawada
发明人: Takehiro Amano , Toshihisa Ogawa , Kensei Yoshikawa , Yoshinori Shiobara , Tatsuhiko Sano , Yutaka Ohuchi , Tohru Tanami , Shoichi Ito , Jiro Sawada
IPC分类号: C07C69/618 , A61K31/215 , A61P29/00 , C07D307/12
CPC分类号: C07D307/12
摘要: A novel carboxylic acid ester having the following general formula ##STR1## wherein R is alkoxyalkyl having 2 to 6 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, tetrahydrofurfuryl, or alkyl having 1 to 6 carbon atoms optionally substituted with 1 or 2 hydroxyl groups, is a useful anti-inflammatory and analgesic agent.
摘要翻译: 具有以下通式的新型羧酸酯:其中R为具有2至6个碳原子的烷氧基烷基,具有5或6个碳原子的环烷基,四氢糠基或具有1至6个碳原子的烷基,任选被1或2个羟基取代 ,是一种有用的消炎止痛剂。
-
公开(公告)号:US4398026A
公开(公告)日:1983-08-09
申请号:US383526
申请日:1982-06-01
申请人: Seiichi Takano , Susumu Otomo , Takehiro Amano
发明人: Seiichi Takano , Susumu Otomo , Takehiro Amano
IPC分类号: A61K31/425 , A61K31/426 , A61P37/04 , C07D277/06 , C07D417/06
CPC分类号: C07D277/06
摘要: A novel thiazolidine derivative having the following general formula ##STR1## wherein R.sup.1 and R.sup.2 are each lower alkyl having 1 to 3 carbon atoms, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of morpholino, piperazino, piperidino and pyrrolidino, or said heterocyclic ring substituted with 1 or 2 methyl groups, and the pharmaceutically acceptable salts thereof are useful immunomodulators.
摘要翻译: 一种具有以下通式的新型噻唑烷衍生物,其中R 1和R 2各自为具有1至3个碳原子的低级烷基,或者R 1和R 2与它们所连接的氮原子一起形成选自以下的杂环: 吗啉代,哌嗪子基,哌啶子基和吡咯烷子基,或被1或2个甲基取代的所述杂环,其药学上可接受的盐是有用的免疫调节剂。
-
-
-
-
-
-
-
-
-